2-[(1E)-tert-butylmethylidene]toluenesulfonyl-hydrazone | 949513-03-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(1E)-tert-butylmethylidene]toluenesulfonyl-hydrazone
• 英文别名: N-(2,2-dimethylpropylideneamino)-4-methylbenzenesulfonamide；P-Toluenesulfonic acid (2,2-dimethylpropylidene)hydrazide；N-[(E)-2,2-dimethylpropylideneamino]-4-methylbenzenesulfonamide
• CAS: 949513-03-5
• 化学式: C₁₂H₁₈N₂O₂S
• 分子量: 254.353
• InChiKey: NLBJMRFPAKOOSM-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(1E)-tert-butylmethylidene]toluenesulfonyl-hydrazone 在 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 生成 5-tert-butyl-3-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4-cyano-3-trifluoromethyl-phenyl)-amide
  参考文献：
  名称：

  Design, Synthesis, and in Vivo SAR of a Novel Series of Pyrazolines as Potent Selective Androgen Receptor Modulators

  摘要：

  A novel series of pyrazolines 2 have been designed, synthesized, and evaluated by in vivo screening as tissue-selective androgen receptor modulators (SARMs). Structure- activity relationships (SAR) were investigated at the R-1 to R-6 positions as well as the core pyrazoline ring and the anilide linker. Overall, strong electron-withdrawing groups at the RI and 2 positions and a small group at the R1 and RI position are optimal for AR agonist activity. The (S)-isomer of 7c exhibits more potent AR agonist activity than the corresponding (R)-isomer. (S)-7c exhibited an overall partial androgenic effect but full anabolic effect via oral administration in castrated rats. It demonstrated a noticeable antiandrogenic effect on prostate in intact rats with endogenous testosterone. Thus, (S)-7c is a tissue-selective nonsteroidal androgen receptor modulator with agonist activity on muscle and mixed agonist and antagonist activity on prostate.

  DOI：

  10.1021/jm0613976
• 作为产物：
  描述：

  对甲苯磺酰肼 、 特戊醛 以 甲醇 为溶剂， 反应 3.0h， 生成 2-[(1E)-tert-butylmethylidene]toluenesulfonyl-hydrazone
  参考文献：
  名称：

  [EN] BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF
  [FR] COMPOSÉS PYRAZOLE CONTENANT DU BORE, COMPOSITIONS COMPRENANT CEUX-CI, MÉTHODES ET UTILISATIONS ASSOCIÉES

  摘要：

  本发明描述了新型含硼吡唑化合物或其药学上可接受的盐、包含它们的制药组合物以及它们的医学用途。本发明化合物具有作为Janus激酶（JAK）抑制剂的活性，并且在治疗或控制炎症、自身免疫性疾病、癌症和其他需要调节JAK的疾病和适应症中有用。还描述了通过给予本文所述化合物来抑制Janus激酶以治疗炎症、自身免疫性疾病、癌症和其他易受抑制Janus激酶的疾病和症状的方法。

  公开号：

  WO2022133420A1

文献信息

• INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Mizuno Kazuhiro

  公开号：US20140057895A1

  公开（公告）日：2014-02-27

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative comprising a 5 membered heterocyclic substituent at 1 position thereof which has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same.

  本发明涉及一种新型吲唑或吡咯吡啶衍生物，其在1位具有一个5成员杂环取代基，具有对5-羟色胺-4受体的激动作用或部分激动作用，以及包含该衍生物的药物组合物。
• [EN] BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF<br/>[FR] COMPOSÉS PYRAZOLE CONTENANT DU BORE, COMPOSITIONS COMPRENANT CEUX-CI, MÉTHODES ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC

  公开号：WO2022133420A1

  公开（公告）日：2022-06-23

  The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

  本发明描述了新型含硼吡唑化合物或其药学上可接受的盐、包含它们的制药组合物以及它们的医学用途。本发明化合物具有作为Janus激酶（JAK）抑制剂的活性，并且在治疗或控制炎症、自身免疫性疾病、癌症和其他需要调节JAK的疾病和适应症中有用。还描述了通过给予本文所述化合物来抑制Janus激酶以治疗炎症、自身免疫性疾病、癌症和其他易受抑制Janus激酶的疾病和症状的方法。
• QUAST H.; KEES F., CHEM. BER., 1981, 114, NO 2, 774-786
  作者：QUAST H.、 KEES F.

  DOI：——

  日期：——
• BERTZ, S. H.;DABBAGH, G., J. ORG. CHEM., 1983, 48, N 1, 116-119
  作者：BERTZ, S. H.、DABBAGH, G.

  DOI：——

  日期：——
• CACCHI S.; LA TORRE F.; MISITI D., SYNTHESIS, 1977, NO 5, 301-303
  作者：CACCHI S.、 LA TORRE F.、 MISITI D.

  DOI：——

  日期：——